secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001493152-24-011077
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma oral LNC-docetaxel shows no toxicity in mouse study; 8x higher dose tolerated without weight loss
--------------------------------------------------------------------------------

- Total docetaxel delivered orally via LNC was >8x IV dose by Day 22; all IV mice lost avg 20% weight, LNC mice maintained weight normal.
- One IV-docetaxel mouse died (32% weight loss); LNC-docetaxel mice had no mortality and weight statistically same as saline controls.
- Daily oral LNC-docetaxel dose 50% higher and total drug 3.5x greater than prior study that showed comparable anti-tumor activity to IV-docetaxel.
- Company plans further evaluation of higher doses in additional tumors and other toxic chemotherapies using LNC platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224011077/0001493152-24-011077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224011077/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer